FDA-cleared profile

ClearRead CT

RIVERAIN TECHNOLOGIES, LLC · CT/CTA · FDA-cleared (510(k))

Authorized purpose: ClearRead CT is a post-processing adjunct for detecting pulmonary nodules on chest CT in an asymptomatic population; it generates a secondary vessel-suppressed lung CT with CADe marks and region descriptors and must be reviewed with the original CT series.

Clinical role
Post-processing support for pulmonary-nodule detection during review of chest CT examinations.
Images and patients
CT/CTA · Chest/lungs
Key limitation
Keep in mind: ClearRead CT is an adjunct and must not be used without the original CT series. The cleared indication is for an asymptomatic population and requires both lungs in the field of view; radiologist judgment remains required.

Overview status: Source-reviewed overview

Report a correction

Evaluation pilot

Before you shortlist

Exact FDA record: K161201 · Agent source review · . This is not clinician review or local acceptance.

Within this record's scope

  • Consider for adjunctive pulmonary-nodule review of asymptomatic chest CT studies with both lungs in view.

Limits to check

  • This record does not support using processed images without the original CT series or extending the indication to another population.

Questions for the vendor and your team

  1. Which licensed detection outputs are included in the quoted release, and which submission supports them?
  2. Can readers review processed and original series together on the local viewer, including missed findings and false marks?

These questions are prompts for evaluation, not claims that licensing, compatibility, performance or price has been confirmed.

Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Image interpretation · source-reviewed 2026-11-12

Agent source review of original FDA labeling; not clinician sign-off or local workflow qualification.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: ClearRead CT is a post-processing adjunct for detecting pulmonary nodules on chest CT in an asymptomatic population; it generates a secondary vessel-suppressed lung CT with CADe marks and region descriptors and must be reviewed with the original CT series.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest/lungs Input: Previously acquired chest CT studies with both lungs in the field of view.
  • Who uses it?Intended users: Radiologists reviewing CT examinations of the chest.
  • What does the software produce?Output: A secondary vessel-suppressed lung CT with CADe marks and region descriptors for review alongside the original CT series.
  • What is its most important limitation?Key limitation: ClearRead CT is an adjunct and must not be used without the original CT series. The cleared indication is for an asymptomatic population and requires both lungs in the field of view; radiologist judgment remains required.

Clinical takeaway. Clinical role: ClearRead CT is a post-processing adjunct for detecting pulmonary nodules on chest CT in an asymptomatic population; it generates a secondary vessel-suppressed lung CT with CADe marks and region descriptors and must be reviewed with the original CT series.

Evidence takeaway. Evidence from the reviewed source record: The FDA package documents software verification and the adjunctive vessel-suppression and CADe workflow; no exact-version independent clinical-outcome claim was promoted.

Evidence context: questions, not a score

Agent transcription of regulatory evidence context, not independent validation, clinical acceptance or a product recommendation. Separate studies and outcomes are not a leaderboard.

K161201 · agent source review 2026-11-09 · exact submission

Existing study anchor: K161201 FDA evidence package for ClearRead CT. Tested version label: ClearRead CT.

What was tested?

A reader study measured localization ROC area and interpretation time with ClearRead CT versus unaided interpretation.

Source section: 510(k) summary, Testing Summary

On which cases and versions?

The K161201 summary does not report the reader-study sample size, site count or detailed composition. The existing study anchor is the exact FDA submission, not an independently verified commercial release.

Source section: 510(k) summary, Testing Summary

What changed?

The summary reports a statistically significant increase in localization ROC area and reduced reading time, without numeric effect sizes or confidence intervals in the reviewed text.

Source section: 510(k) summary, Testing Summary

What does this not establish?

The summary does not establish patient outcomes, downstream work-up burden, local workflow savings or performance for another release. Unreported denominators and confidence intervals remain unknown.

Source section: 510(k) summary, Testing Summary

Study design, population and missing context
evidence Role
Multi-reader multi-case reader validation and software verification.

reader study · 510(k) summary, Testing Summary

design
Reader study comparing use of ClearRead CT with unaided interpretation.

reader study · 510(k) summary, Testing Summary

setting
Not established: The reviewed regulatory summary does not establish this field for this study context.
training Population
Not established: The reviewed regulatory summary does not establish this field for this study context.
evaluation Population
CT chest examinations used in the reader validation; the summary does not state the number of cases.

reader study · 510(k) summary, Testing Summary

reference Standard
Not established: The reviewed regulatory summary does not establish this field for this study context.
comparator
The same task with ClearRead CT versus unaided interpretation.

reader study · 510(k) summary, Testing Summary

sites
Not established: The reviewed regulatory summary does not establish this field for this study context.
scanner Protocol
Not established: The reviewed regulatory summary does not establish this field for this study context.
sample Composition
Not established: The reviewed regulatory summary does not establish this field for this study context.
sponsor Involvement
Manufacturer-prepared regulatory summary submitted by Riverain. Independent-investigator status is not established.

regulatory summary · 510(k) summary, Testing Summary

Public-label constraints

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Exact FDA submission K161201 · agent source review 2026-11-09 · ClearRead CT

Authorized population

Asymptomatic population undergoing CT examinations of the chest.

Label age limits

Not established: No numerical age bound or explicit all-ages statement in the reviewed labeling sections. Study ages do not establish authorized age limits.

Documented care setting

Not established: No explicit constraint transcribed from the reviewed labeling sections. Unknown does not mean unrestricted.

Labeled anatomy

Chest; both lungs must be in the field of view.

Acquisition constraints

Requires both lungs in the field of view and use with the original CT series.

Exclusions and human review

Adjunctive information, not intended to be used without the original CT series.

Purpose
ClearRead CT is a post-processing adjunct for detecting pulmonary nodules on chest CT in an asymptomatic population; it generates a secondary vessel-suppressed lung CT with CADe marks and region descriptors and must be reviewed with the original CT series.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Post-processing support for pulmonary-nodule detection during review of chest CT examinations.
  • Exact FDA submission
  • Checked 2026-11-12
Required input
Previously acquired chest CT studies with both lungs in the field of view.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
A secondary vessel-suppressed lung CT with CADe marks and region descriptors for review alongside the original CT series.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Radiologists reviewing CT examinations of the chest.
  • Exact FDA submission
  • Checked 2026-11-12

The Indications for Use name only the radiologist as the user; no other user class or qualification is stated.

Limitations
ClearRead CT is an adjunct and must not be used without the original CT series. The cleared indication is for an asymptomatic population and requires both lungs in the field of view; radiologist judgment remains required.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The FDA package documents software verification and the adjunctive vessel-suppression and CADe workflow; no exact-version independent clinical-outcome claim was promoted.
  • Exact FDA submission
  • Checked 2026-09-04

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The FDA package documents software verification and the adjunctive vessel-suppression and CADe workflow; no exact-version independent clinical-outcome claim was promoted.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No single product-level sensitivity value was promoted because the reviewed FDA material is workflow, module, sequence, or population specific.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No single product-level specificity value was promoted because the reviewed FDA material is workflow, module, sequence, or population specific.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K161201 FDA evidence package for ClearRead CT

  • DesignFDA 510(k) verification and validation evidence described in the exact submission
  • PopulationChest/lungs
  • Scopeexact submission
  • Tested versionClearRead CT
  • IndependenceSponsor or vendor study

K161201

Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no candidate record for K161201; no exact native submission identifier match was found.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed CMS material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Previously acquired chest CT studies with both lungs in the field of view.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K161201: ClearRead CT

  2. Routing

    Source context, not route validation: The FDA package describes CT post-processing and secondary-series output; exact DICOM routing, archive behavior, and local worklist integration require testing.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K161201: ClearRead CT

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact installed deployment, hosting, service, and operational boundary is not established by the reviewed public FDA material.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: A secondary vessel-suppressed lung CT with CADe marks and region descriptors for review alongside the original CT series.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K161201: ClearRead CT

  5. Viewer/worklist/report

    Unresolved route: A secondary vessel-suppressed lung CT with CADe marks and region descriptors for review alongside the original CT series.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K161201: ClearRead CT

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The FDA package describes CT post-processing and secondary-series output; exact DICOM routing, archive behavior, and local worklist integration require testing.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K161201 by exact software, hardware, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: ClearRead CT is an adjunct and must not be used without the original CT series. The cleared indication is for an asymptomatic population and requires both lungs in the field of view; radiologist judgment remains required.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map the installed product, build, options, population, anatomy, inputs, outputs, and enabled functions to K161201 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Deployment boundary

The exact installed deployment, hosting, service, security, and operational boundary remains unverified and requires site-specific confirmation.

exact submission · checked 2026-09-04

FDA-described deployment details do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The FDA package describes CT post-processing and secondary-series output; exact DICOM routing, archive behavior, and local worklist integration require testing.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. ClearRead CT is an adjunct and must not be used without the original CT series. The cleared indication is for an asymptomatic population and requires both lungs in the field of view; radiologist judgment remains required.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price or product-specific reimbursement was established in the reviewed public material.

Lifecycle monitoring

Monitor K161201 by exact software, hardware, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: ClearRead CT is an adjunct and must not be used without the original CT series. The cleared indication is for an asymptomatic population and requires both lungs in the field of view; radiologist judgment remains required.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K161201
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Chest/lungs
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2016-09-09
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-04Last searched
25Fields reviewed
11Source classes checked
0Screened PubMed leads
2Screened trial leads
0Unreviewed FDA recall leads

Screened two trial records. NCT02440139 is manufacturer-scoped to Riverain lung-nodule software but does not identify ClearRead CT, K161201, or a tested version; NCT06514248 is a different vendor, so both are quarantined. The current discovery snapshot contains 0 PubMed and 2 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Care setting: Not publicly available - checked 2026-11-12 - Exact FDA submission

    The K161201 Indications for Use and 510(k) summary do not state a care setting. Unknown does not mean unrestricted.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared product version was established. Obtain a written quote separating license, implementation, interfaces, compute, storage, training, support, upgrades, renewal, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact installed deployment, hosting, service, and operational boundary is not established by the reviewed public FDA material.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The FDA decision material does not establish the complete security posture for the exact product and deployment. Obtain architecture, identity, audit, encryption, retention, support-access, vulnerability-management, and incident-response evidence.

  • Installation timeline: Not yet reviewed
  • Training: Not publicly available - checked 2026-11-12 - Exact FDA submission

    The K161201 FDA material names the radiologist as the user but states no training, qualification, or competency requirement. Obtain onboarding and competency documentation for the exact release from the vendor.

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K161201: ClearRead CT

    U.S. Food and Drug Administration - Published 2016-09-09 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. ClearRead CT model card (K161201)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K161201 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K254075

Synapse Lung Nodule AI

Fujifilm Corporation

Authorized purpose: Concurrent-reader aid for a radiologist detecting pulmonary nodules during review of chest CT examinations in the lung cancer screening population under screening protocols.

Modality
CT/CTA
Anatomy
Chest/lungs; pulmonary nodules
Decision
2026-05-27
FDA-cleared K251474

Median LCS (internal name) / eyonis LCS (trade name) (1.0)

Median Technologies

eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2026-02-06
FDA-cleared K251769

RevealAI-Lung

Precision Medical Ventures, Inc. Dba Revealdx

Authorized purpose: Characterization and relative cancer-risk assessment of incidentally detected pulmonary nodules 6-15 mm in adults, with use as one input to follow-up and clinical decision-making under published guidelines; not lung-cancer screening

Modality
CT/CTA
Anatomy
Pulmonary nodules in the lungs
Decision
2026-01-30

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

Correction policy and limits · Public repository change history